Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Jiantebo Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Jiantebo Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jiantebo Biotechnology
Manufacturer of a biopharmaceutical products intended to translate a newly discovered IL-27 target into therapies and health products. The company offers IL-27-based oral nutraceuticals, complex probiotics, next-generation antibodies, and chemical drug pipelines, enabling people with metabolic disorders and chronic diseases to access innovative treatments and preventive interventions.
- Sector
- Healthcare
- HQ
- Zhuhai, China
- Founded
- 2021
- Website
- zhuhaijiantebo.com/
- Ownership
- Privately Held (backing)
Jiantebo Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jiantebo Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jiantebo Biotechnology in its N-PORT filings yet. We sweep new filings monthly.